Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Blenrep (Belantamab Mafodotin) in Combination Receives Breakthrough Therapy Designation in China for Treatment of Relapsed/refractory Multiple Myeloma
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
Fulcrum Crashes as GSK-partnered Lead Program Fails
Express News | Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
